Redefining Retinal Resilience: Coave's Suprachoroidal Bet on Wet AMD

PARIS, France – October 05, 2026 – In the pursuit of consistent value creation within the biotechnology sector, few therapeutic areas offer as clear a dichotomy between temporary fixes and permanent solutions as ophthalmology. For decades, the management of neovascular age-related macular degeneration (wet AMD) has been defined by a grueling regimen of chronic intraocular injections. It is a classic example of a recurring revenue model built on patient burden. However, a structural shift is underway, driven by companies seeking to replace this continuous intervention with one-time, durable gene therapies.

At the 26th Euretina Congress in Vienna, Coave Therapeutics, a Paris-based biotechnology firm, presented compelling preclinical data that may well position it as a formidable contender in this high-stakes arena. The company’s lead retinal gene therapy program, CoTx-101, demonstrated unprecedented expression levels and targeted delivery in non-human primates (NHPs), signaling a potential breakthrough in how we approach retinal disease. By combining a novel suprachoroidal delivery route with an AI-engineered dual-pathway mechanism, Coave is not merely iterating on existing therapies; it is attempting to rewrite the mechanics of ocular resilience.

Decoding the Delivery Hurdle

To understand the significance of Coave’s recent data, one must first understand the headwinds facing ocular gene therapy. The primary bottleneck in the field is rarely the genetic payload itself; rather, it is the delivery vehicle. Traditional approaches have relied on either intravitreal or subretinal injections, both of which carry significant compromises.

Intravitreal injections—delivering the vector directly into the fluid-filled center of the eye—are routine and easily performed in a clinic. However, they often expose the anterior segment of the eye to the viral vector, triggering robust inflammatory responses and neutralizing antibodies that can blunt the therapy's efficacy. Conversely, subretinal delivery places the vector precisely where it is needed, but requires highly specialized, invasive vitrectomy surgery, limiting patient access and increasing the risk of surgical complications.

Coave Therapeutics is navigating this challenge by targeting the suprachoroidal space (SCS), a potential space between the sclera and the choroid. This route offers a "best of both worlds" paradigm: it can be accessed via an in-office procedure, much like an intravitreal injection, yet it compartmentalizes the therapy to the posterior segment of the eye, akin to subretinal delivery.

The data presented at Euretina by Dr. Nora Dimon, Coave's VP of Clinical Development, underscores the potency of this approach. Coave’s proprietary ligand-conjugated suprachoroidal vector, coAAV-SCS, achieved an astonishing 120-fold higher expression in the retina and RPE-choroid compared to existing AAV capsids in NHP models. Furthermore, head-to-head studies revealed reproducible targeting of the critical RPE and photoreceptor cells, with severely limited anterior segment exposure. The result is a highly favorable inflammatory profile, effectively bypassing the immunogenic landmines that have derailed previous gene therapy candidates.

AI-Engineered Biology Meets Ocular Delivery

While the delivery vehicle is critical, a therapy's ultimate permanence is dictated by its mechanism of action. Wet AMD is characterized by abnormal blood vessel growth and fluid leakage in the macula, traditionally driven by Vascular Endothelial Growth Factor (VEGF). The current standard of care relies on biologic drugs like aflibercept to inhibit VEGF, but the disease often involves multiple angiogenic pathways.

Here, Coave is leveraging the intersection of generative artificial intelligence and computational biology to build a wider moat. Through its proprietary ALIGATER (Advanced Vectors-Ligand Conjugates) platform, the company utilized AI and machine learning to screen more than 200,000 constructs. The goal was to engineer a lead therapeutic cassette capable of efficiently and simultaneously secreting both anti-VEGF and anti-Ang-2 proteins.

This dual-inhibition strategy is a direct response to the complex biology of wet AMD. By targeting both VEGF and Angiopoietin-2 (Ang-2), CoTx-101 aims to stabilize blood vessels and reduce vascular leakage more comprehensively than VEGF inhibition alone. In a pharmacokinetic NHP study, the coAAV-SCS vector successfully delivered higher posterior segment levels of aflibercept than clinical comparator vectors, reaching concentrations that are clinically meaningful.

"These data reinforce the rationale behind CoTx-101's design, pairing a ligand-conjugated suprachoroidal capsid with a dual-pathway cassette to form a potentially best-in-class gene therapy for the treatment of wet AMD," said Rodolphe Clerval, Chief Executive Officer of Coave Therapeutics. "We have demonstrated that our vector delivers clinically meaningful anti-VEGF levels to the back of the eye, and look forward to continuing work on our lead program as we advance towards the clinic."

Benchmarking the Competitive Landscape

The race to commercialize a one-time gene therapy for wet AMD is intensely competitive, serving as a proving ground for next-generation biotech platforms. CoTx-101 is entering a field currently dominated by advanced clinical-stage programs, most notably REGENXBIO’s RGX-314 and 4D Molecular Therapeutics’ 4D-150.

REGENXBIO is attacking the problem on two fronts. Its subretinal delivery program for RGX-314 is currently in pivotal Phase 3 trials, having demonstrated a dramatic 60-80% reduction in the need for ongoing injections in earlier studies. Concurrently, the company is exploring suprachoroidal delivery via Clearside Biomedical's microinjector, with Phase 2 data showing significant reductions in injection burden.

Meanwhile, 4D Molecular Therapeutics is championing the intravitreal route with 4D-150, currently in Phase 3 trials. Utilizing a customized intravitreal vector (R100) and a dual-transgene payload, 4D-150 has shown robust durability, with recent Phase 2b data highlighting a 78% reduction in supplemental injections over two years.

Against this backdrop, Coave’s competitive positioning hinges on its highly differentiated technology stack. While RGX-314 relies on traditional AAV8 for its suprachoroidal delivery, Coave’s coAAV-SCS is specifically ligand-conjugated to optimize tissue specificity and penetration from the suprachoroidal space. If the 120-fold expression advantage seen in non-human primates translates to human subjects, CoTx-101 could theoretically achieve superior efficacy at lower, safer viral doses. Furthermore, the AI-optimized dual-pathway cassette offers a mechanistic advantage over single-target therapies, aligning with the broader industry shift toward multi-specific biologic interventions.

Navigating the Path to the Clinic

For investors and industry observers, the transition from compelling preclinical data to clinical execution is the ultimate litmus test of a company's resilience. Coave Therapeutics appears well-capitalized to navigate this crucial phase. Backed by a syndicate of leading international life sciences investors, the company secured €32 million in a Series A financing round in January 2025, co-led by Novo Holdings A/S and Bpifrance, building upon a previous €33.1 million Series B in 2021.

This financial runway is critical as Coave prepares to advance CoTx-101 and a second development candidate into IND/CTA-enabling studies throughout 2026. If these regulatory hurdles are cleared, the company is poised to initiate Phase 1/2 human trials for CoTx-101 in late 2026 or early 2027.

The broader implications of Coave’s progress extend beyond a single asset. The ALIGATER platform and the underlying ligand-conjugation technology represent a modular approach to gene therapy design. By demonstrating that AI-guided engineering can solve the fundamental delivery and expression challenges in the eye, Coave is laying the groundwork for a broader pipeline targeting rare CNS and other ocular diseases.

In an unpredictable global healthcare landscape marked by pricing pressures and demand for undeniable clinical differentiation, the true winners will be those who replace chronic disease management with functional cures. Coave Therapeutics has laid out a compelling scientific rationale for how to achieve this in wet AMD. As the company transitions from the laboratory to the clinic, the industry will be watching closely to see if this suprachoroidal bet can deliver on its promise of permanent, structural value creation.